Payment overview · 2025
General Payments
$441.97
24 reported records · 16 companies
Healthcare provider profile · identity verified
Jenson Abraham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DENISON, TX · NPI 1205074135
Verified facts
What the public records show
CMS Open Payments records show Jenson Abraham, M.D. received $441.97 in general payments during 2025 across 24 reported records.
Lilly USA, LLC accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.37 | 14.1% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.81 | 10.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.29 | 10.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.50 | 7.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.07 | 7.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.45 | 7.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.92 | 5.2% | 1 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.82 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.39 | 5.1% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $20.09 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.13 | 4.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.72 | 4.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.43 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.28 | 3.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.47 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.23 | 3.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $441.97 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.81 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.49 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.49 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $31.45 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.23 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 94 |
| Gabapentin | Gabapentin | 288 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 51 |
| Lisinopril | Lisinopril | 243 | 74 |
| Furosemide | Furosemide | 229 | 71 |
| Alprazolam | Alprazolam | 221 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 71 |
| Tramadol Hcl | Tramadol Hcl | 196 | 48 |
| Losartan Potassium | Losartan Potassium | 194 | 65 |
| Montelukast Sodium | Montelukast Sodium | 194 | 56 |
| Potassium Chloride | Potassium Chloride | 162 | 59 |
| Metformin Hcl | Metformin Hcl | 141 | 48 |
| Trazodone Hcl | Trazodone Hcl | 136 | 40 |
| Jardiance | Empagliflozin | 135 | 39 |
| Eliquis | Apixaban | 126 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 47 |
| Finasteride | Finasteride | 118 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 34 |
| Carvedilol | Carvedilol | 107 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 30 |
| Allopurinol | Allopurinol | 96 | 32 |
| Xarelto | Rivaroxaban | 96 | 19 |
| Memantine Hcl | Memantine Hcl | 95 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 21 |
| Omeprazole | Omeprazole | 91 | 28 |
| Prednisone | Prednisone | 83 | 46 |
| Mounjaro | Tirzepatide | 82 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 29 |
| Spironolactone | Spironolactone | 79 | 26 |
| Pregabalin | Pregabalin | 78 | 27 |
| Glimepiride | Glimepiride | 77 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Simvastatin | Simvastatin | 70 | 27 |
| Warfarin Sodium | Warfarin Sodium | 69 | 16 |
| Temazepam | Temazepam | 68 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 16 |
| Meloxicam | Meloxicam | 66 | 27 |
| Ozempic | Semaglutide | 60 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 42 |
| Clonazepam | Clonazepam | 58 | 15 |
| Azithromycin | Azithromycin | 57 | 52 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | suppressed |
| Topiramate | Topiramate | 54 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 52 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Propranolol Hcl | Propranolol Hcl | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Terazosin Hcl | Terazosin Hcl | 44 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Methocarbamol | Methocarbamol | 40 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 29 |
| Sertraline Hcl | Sertraline Hcl | 38 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Levofloxacin | Levofloxacin | 34 | 24 |
| Fluconazole | Fluconazole | 33 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 22 |
| Famotidine | Famotidine | 31 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | 11 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 19 |
| Estradiol | Estradiol | 24 | 14 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.97 · 24 records | Lilly USA, LLC | AREXVY, Dexcom G6 Transmitter, JARDIANCE, JOURNAVX, KISUNLA, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, Korlym, MOUNJARO, REXULTI, SPRAVATO, TERIPARATIDE, TRELEGY ELLIPTA, VIBERZI, VOQUEZNA, Veozah, XYOSTED, ZEPBOUND, ZYNRELEF | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error